Hormona is on a mission to make hormone health understandable and actionable for women everywhere, replacing guesswork and lab visits with at-home testing and AI-driven insight. The company's clinical-grade urine tests measure hormones such as progesterone, estrogen, and follicle-stimulating hormone, delivering fully quantitative results in roughly 15 minutes without blood draws or clinic appointments. Users scan the test strip with their phone camera, and Hormona's AI scanner converts the image into real-time, quantitative hormone readings.
The Hormona app ties those readings into a broader picture of a woman's health. It tracks the menstrual cycle, predicts symptoms like PMS and period timing, and offers personalized, cycle-synced nutrition and lifestyle guidance. Daily insights and expert content from endocrinologists, gynecologists, and nutritionists help users interpret what their hormone patterns mean and what to do about them, while long-term tracking surfaces trends that a single snapshot would miss.
Beyond general wellness tracking, Hormona offers specialized programs, including a wellness hormone test for everyday monitoring and a perimenopause-specific test and support program for women navigating that transition. The company says its tests are the first of their kind to be fully quantitative across the full clinical range, with over 90% accuracy compared to standard venous blood samples, and its app has been downloaded in more than 190 countries.
Founded in 2020 and co-founded by CEO Karolina Lofqvist and COO Jasmine Tagesson, Hormona raised a EUR 7.8 million seed round (about $6.7 million) in May 2025 led by Voima Ventures and co-led by SuperNode Global, with participation from DLF Ventures, Nascent Invest, and Techstars. The funding supports expansion of its testing portfolio and AI capabilities as Hormona scales its at-home, AI-powered approach to women's hormonal health.